Page 132 - 《中国药房》2024年11期
P. 132
statistics 2020:GLOBOCAN estimates of incidence and induction of a G2/M cell cycle checkpoint[J]. Proc Natl
mortality worldwide for 36 cancers in 185 countries[J]. Acad Sci U S A,1999,96(7):3706-3711.
CA Cancer J Clin,2021,71(3):209-249. [17] HIKISZ P,KILIAŃSKA Z M. PUMA,a critical mediator
[ 3 ] 支修益,师建国,田艳涛,等 . 《2022 年中国肺癌患者生 of cell death:one decade on from its discovery[J]. Cell
存质量白皮书》要点解读[J]. 中国胸心血管外科临床杂 Mol Biol Lett,2012,17(4):646-669.
志,2023,30(8):1083-1088. [18] VIARD-LEVEUGLE I,VEYRENC S,FRENCH L E,
ZHI X Y,SHI J G,TIAN Y T,et al. Interpretation of the et al. Frequent loss of Fas expression and function in human
key points of the 2022 White Paper on the Quality of Life lung tumors with overexpression of FasL in small cell
of Chinese Lung Cancer Patients[J]. Chin J Clin Thorac lung carcinoma[J]. J Pathol,2003,201(2):268-277.
Cardiovasc Surg,2023,30(8):1083-1088. [19] HADJI A,CEPPI P,MURMANN A E,et al. Death in‐
[ 4 ] WANG H L,GUO M,WEI H D,et al. Targeting p53 path‐ duced by CD95 or CD95 ligand elimination[J]. Cell Rep,
ways:mechanisms,structures,and advances in therapy[J]. 2014,7(1):208-222.
Signal Transduct Target Ther,2023,8(1):92. [20] KREIS N N,LOUWEN F,YUAN J P. The multifaceted
[ 5 ] WU S Q,SUN Z,GUO Z H,et al. The effectiveness of p21 (Cip1/Waf1/CDKN1A) in cell differentiation,migra‐
blood-activating and stasis-transforming traditional Chinese tion and cancer therapy[J]. Cancers,2019,11(9):1220.
medicines (BAST) in lung cancer progression:a compre‐ [21] CHEN J,HUANG X,HALICKA D,et al. Contribution of
hensive review[J]. J Ethnopharmacol,2023,314:116565. p16INK4a and p21CIP1 pathways to induction of prema‐
[ 6 ] HASSIN O,OREN M. Drugging p53 in cancer:one pro‐ ture senescence of human endothelial cells:permissive
tein,many targets[J]. Nat Rev Drug Discov,2023,22(2): role of p53[J]. Am J Physiol Heart Circ Physiol,2006,290
127-144. (4):H1575-H1586.
[ 7 ] WEI C L,WU Q,VEGA V B,et al. A global map of p53 [22] KORTLEVER R M,HIGGINS P J,BERNARDS R. Plas‐
transcription-factor binding sites in the human genome[J]. minogen activator inhibitor-1 is a critical downstream tar‐
Cell,2006,124(1):207-219. get of p53 in the induction of replicative senescence[J].
[ 8 ] MCKAY B C,CHEN F,PERUMALSWAMI C R,et al. Nat Cell Biol,2006,8(8):877-884.
The tumor suppressor p53 can both stimulate and inhibit [23] KANG R,KROEMER G,TANG D L. The tumor suppres‐
ultraviolet light-induced apoptosis[J]. Mol Biol Cell, sor protein p53 and the ferroptosis network[J]. Free Radic
2000,11(8):2543-2551. Biol Med,2019,133:162-168.
[ 9 ] HERNÁNDEZ BORRERO L J,EL-DEIRY W S. Tumor [24] CHU B,KON N,CHEN D L,et al. ALOX12 is required
suppressor p53:biology,signaling pathways,and thera‐ for p53-mediated tumor suppression through a distinct fer‐
peutic targeting[J]. Biochim Biophys Acta Rev Cancer, roptosis pathway[J]. Nat Cell Biol,2019,21(5):579-591.
2021,1876(1):188556. [25] MAO C,LIU X G,ZHANG Y L,et al. DHODH-mediated
[10] WANG Y H,HO T L F,HARIHARAN A,et al. Rapid re‐ ferroptosis defense is a targetable vulnerability in cancer
cruitment of p53 to DNA damage sites directs DNA repair [J]. Nature,2021,593(7860):586-590.
choice and integrity[J]. Proc Natl Acad Sci U S A,2022, [26] KASTENHUBER E R,LOWE S W. Putting p53 in con‐
119(10):e2113233119. text[J]. Cell,2017,170(6):1062-1078.
[11] KIM J,KUNDU M,VIOLLET B,et al. AMPK and [27] LUJAMBIO A,LOWE S W. The microcosmos of cancer
mTOR regulate autophagy through direct phosphorylation [J]. Nature,2012,482(7385):347-355.
of Ulk1[J]. Nat Cell Biol,2011,13(2):132-141. [28] SHIOZAWA Y,NIE B,PIENTA K J,et al. Cancer stem
[12] LEYTENS A,DENGJEL J. DRAMing for autophagy[J]. cells and their role in metastasis[J]. Pharmacol Ther,
FEBS J,2022,289(13):3731-3734. 2013,138(2):285-293.
[13] XING Y H,WEI X Q,LIU Y C,et al. Autophagy inhibi‐ [29] ZHANG Z C,OH M,SASAKI J I,et al. Inverse and reci-
tion mediated by MCOLN1/TRPML1 suppresses cancer procal regulation of p53/p21 and Bmi-1 modulates vascu‐
metastasis via regulating a ROS-driven TP53/p53 pathway logenic differentiation of dental pulp stem cells[J]. Cell
[J]. Autophagy,2022,18(8):1932-1954. Death Dis,2021,12(7):644.
[14] ENGELAND K. Cell cycle arrest through indirect tran‐ [30] 李修身,周岱翰. 清金得生片联合化疗治疗中晚期非小
scriptional repression by p53:I have a DREAM[J]. Cell 细胞肺癌回顾性临床研究[J]. 中医肿瘤学杂志,2020,2
Death Differ,2018,25(1):114-132. (5):24-28.
[15] HERMEKING H,LENGAUER C,POLYAK K,et al. 14- LI X S,ZHOU D H. Retrospective clinical study of
3-3 sigma is a p53-regulated inhibitor of G2/M progression Qingjin desheng tablet combined with chemotherapy in
[J]. Mol Cell,1997,1(1):3-11. the treatment of advanced non-small cell lung cancer[J]. J
[16] WANG X W,ZHAN Q,COURSEN J D,et al. GADD45 Oncol Chin Med,2020,2(5):24-28.
· 1406 · China Pharmacy 2024 Vol. 35 No. 11 中国药房 2024年第35卷第11期